Literature DB >> 30833063

Eliminating hepatitis C.

Talha Burki.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 30833063     DOI: 10.1016/S1473-3099(19)30073-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients.

Authors:  Hsu-Heng Yen; Pei-Yuan Su; I-Ling Liu; Ya-Yuei Zeng; Siou-Ping Huang; Yu-Chun Hsu; Chia-Wei Yang; Yang-Yuan Chen
Journal:  PeerJ       Date:  2021-03-16       Impact factor: 2.984

2.  Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.

Authors:  Hsu-Heng Yen; Pei-Yuan Su; Ya-Huei Zeng; I-Ling Liu; Siou-Ping Huang; Yu-Chun Hsu; Yang-Yuan Chen; Chia-Wei Yang; Shun-Sheng Wu; Kun-Ching Chou
Journal:  PLoS One       Date:  2020-08-13       Impact factor: 3.240

3.  Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis.

Authors:  Hsu-Heng Yen; Yang-Yuan Chen; Jun-Hung Lai; Hung-Ming Chen; Chih-Ta Yao; Siou-Ping Huang; I-Ling Liu; Ya-Huei Zeng; Fang-Chi Yang; Fu-Yuan Siao; Mei-Wen Chen; Pei-Yuan Su
Journal:  J Clin Med       Date:  2022-03-27       Impact factor: 4.241

4.  Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.

Authors:  Hui Jun Zhou; Jing Cao; Hui Shi; Nasheen Naidoo; Sherehe Semba; Pei Wang; Yi Fan Fan; Shui Cheng Zhu
Journal:  Front Public Health       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.